Pyxis Oncology's EPS (Basic) for the
three
months ended in Dec. 2023 was $-0.33.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.84.
Pyxis Oncology's EPS without NRI for the
three
months ended in Dec. 2023 was $-0.33.
Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.84.
During the past 3 years, the average EPS without NRIGrowth Rate was -47.20% per year.
During the past 5 years, Pyxis Oncology's highest 3-Year average EPS without NRI Growth Rate was -47.20% per year. The lowest was -207.10% per year. And the median was -127.15% per year.
Pyxis Oncology Earnings per Share (Diluted) Historical Data
The historical data trend for Pyxis Oncology's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Pyxis Oncology's Earnings per Share (Diluted)
For the Biotechnology subindustry, Pyxis Oncology's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pyxis Oncology's PE Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pyxis Oncology's PE Ratio distribution charts can be found below:
* The bar in red indicates where Pyxis Oncology's PE Ratio falls into.
Pyxis Oncology Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Pyxis Oncology's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.84
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
Pyxis Oncology (NAS:PYXS) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Pyxis Oncology Earnings per Share (Diluted) Related Terms
Thank you for viewing the detailed overview of Pyxis Oncology's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Pyxis Oncology (Pyxis Oncology) Business Description
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve the quality of life for patients. It develops the product candidates to directly kill tumor cells and address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Its lead ADC product candidate is PYX-201, an investigational human IgG1 isotype site-specifically conjugated with an auristatin toxin targeting EDB that initially develop for solid tumors, including NSCLC, hormone receptor-positive breast, ovarian and thyroid cancer. The IO product candidate is PYX-106, designed to block Siglec-15-mediated suppression of T-cell proliferation and function.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PYXS has been successfully added to your 